title: Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.
abstract: OBJECTIVE
  To evaluate the impact of anti-tumor necrosis factor (anti-TNF) therapies on quality of life (QOL) and functional status in psoriatic arthritis (PsA) patients and study potential predictors for QOL improvements.
  
  
  METHODS
  The study was based on a cohort of 596 PsA patients receiving anti-TNF therapies. Changes in functional status and QOL were assessed using the Health Assessment Questionnaire (HAQ) and Short Form 36 (SF-36) questionnaire on a 6-month basis. The Short Form 6D (SF-6D) was calculated as a utility score. Univariate and multivariate linear regression models were developed to examine potential predictors of QOL improvements at 6 months, using a range of demographic, baseline disease-specific, and therapeutic variables.
  
  
  RESULTS
  At 6 months, significant improvements in all SF-36 subscale scores were found, with the greatest percentage improvement from baseline related to physical role (113.8%; 95% confidence interval [95% CI] 102.6, 125.0). The percent improvement for the physical component scale was 53.2% (95% CI 44.5, 61.9) at 6 months, whereas that for the mental component scale was 16.9% (95% CI 14.7, 19.2). The mean +/- SD SF-6D score was 0.58 +/- 0.07 at baseline, and this improved to 0.63 +/- 0.06 at 6 months. The median HAQ score at baseline was 1.88 (interquartile range [IQR] 1.38-2.25) for the entire cohort, and this improved to 1.25 (IQR 0.63-1.88) at 6 months. Improvements in Disease Activity Score in 28 joints at 6 months were found to be significantly associated with QOL improvements at the same time point.
  
  
  CONCLUSIONS
  Anti-TNF therapy is associated with improvement in both physical and mental status in PsA patients. These improvements were most substantial in patients who also had improvements in their disease activity.
authors.affiliation: School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
authors.forename: Amr A
authors.initials: AA
authors.lastname: Saad
authors.forename: Darren M
authors.initials: DM
authors.lastname: Ashcroft
authors.forename: Kath D
authors.initials: KD
authors.lastname: Watson
authors.forename: Deborah P M
authors.initials: DP
authors.lastname: Symmons
authors.forename: Peter R
authors.initials: PR
authors.lastname: Noyce
authors.forename: Kimme L
authors.initials: KL
authors.lastname: Hyrich
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001685:Biological Factors / Q000627:therapeutic use*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D020127:Recovery of Function; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001685:Biological Factors; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
references.citation: J Rheumatol. 1993 Mar;20(3):557-60
references.pmid: 8478873
references.citation: Lancet. 2000 Jul 29;356(9227):385-90
references.pmid: 10972371
references.citation: J Rheumatol. 1998 Nov;25(11):2146-55
references.pmid: 9818657
references.citation: Curr Opin Rheumatol. 2004 Jul;16(4):350-6
references.pmid: 15201596
references.citation: Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii28-9
references.pmid: 14532144
references.citation: Arthritis Rheum. 2008 Feb 15;59(2):234-40
references.pmid: 18240258
references.citation: J Postgrad Med. 2007 Jan-Mar;53(1):63-71
references.pmid: 17244977
references.citation: Arthritis Res Ther. 2009;11(2):R52
references.pmid: 19356232
references.citation: J Rheumatol. 2007 May;34(5):1040-50
references.pmid: 17444593
references.citation: Arthritis Rheum. 2001 Apr;45(2):151-8
references.pmid: 11324779
references.citation: Mayo Clin Proc. 1978 Aug;53(8):511-8
references.pmid: 682678
references.citation: Baillieres Clin Rheumatol. 1995 May;9(2):319-29
references.pmid: 7656343
references.citation: Semin Arthritis Rheum. 2009 Feb;38(4):320-35
references.pmid: 18304610
references.citation: Arthritis Rheum. 1980 Feb;23(2):137-45
references.pmid: 7362664
references.citation: Rheumatology (Oxford). 2008 Jul;47(7):1000-5
references.pmid: 18420660
references.citation: Arthritis Rheum. 2005 Oct;52(10):3279-89
references.pmid: 16200601
references.citation: Arthritis Rheum. 2005 Aug;52(8):2506-12
references.pmid: 16052584
references.citation: Ann Rheum Dis. 2005 Aug;64(8):1150-7
references.pmid: 15677701
references.citation: Ann Rheum Dis. 2007 Aug;66(8):1038-42
references.pmid: 17213251
references.citation: Arthritis Rheum. 2004 Jul;50(7):2264-72
references.pmid: 15248226
references.citation: J Rheumatol. 1995 May;22(5):886-93
references.pmid: 8587077
references.citation: Ann Rheum Dis. 2008 Mar;67(3):364-9
references.pmid: 17644547
references.citation: Pharmacoeconomics. 1999 Nov;16(5 Pt 1):449-58
references.pmid: 10662392
references.citation: J Rheumatol. 2007 May;34(5):1167-70
references.pmid: 17477480
references.citation: Ann Rheum Dis. 2010 Feb;69(2):352-7
references.pmid: 19282310
references.citation: Stat Med. 1999 Mar 30;18(6):681-94
references.pmid: 10204197
references.citation: Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7
references.pmid: 15708927
references.citation: Rheumatology (Oxford). 2005 Mar;44(3):390-7
references.pmid: 15695305
references.citation: J Dermatolog Treat. 2006;17(6):355-8
references.pmid: 17853309
references.citation: Arthritis Rheum. 2006 Sep;54(9):2784-92
references.pmid: 16947781
references.citation: J Rheumatol. 2005 Oct;32(10):1918-22
references.pmid: 16206347
references.citation: Arthritis Rheum. 2005 Apr;52(4):1227-36
references.pmid: 15818699
references.citation: J Rheumatol. 1990 Jun;17(6):809-12
references.pmid: 2388203
references.citation: Health Econ. 2008 Jul;17(7):815-32
references.pmid: 17893863
references.citation: Arthritis Rheum. 1998 Jun;41(6):1103-10
references.pmid: 9627021
references.citation: Ann Rheum Dis. 2004 Feb;63(2):162-9
references.pmid: 14722205
references.citation: J Health Econ. 2002 Mar;21(2):271-92
references.pmid: 11939242
references.citation: Arthritis Rheum. 2000 Jul;43(7):1478-87
references.pmid: 10902749
references.citation: Ann Rheum Dis. 2006 Oct;65(10):1373-8
references.pmid: 16644783
references.citation: J Rheumatol. 2000 May;27(5):1247-50
references.pmid: 10813295
references.citation: Ann Rheum Dis. 2007 Feb;66(2):163-8
references.pmid: 17046964
references.citation: J Rheumatol. 2008 Aug;35(8):1613-21
references.pmid: 18597399
references.citation: Arthritis Rheum. 1995 Jan;38(1):44-8
references.pmid: 7818570
references.citation: Arthritis Res Ther. 2007;9(5):R103
references.pmid: 17922913
references.citation: J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
references.pmid: 15083780
references.citation: Br J Rheumatol. 1986 May;25(2):206-9
references.pmid: 3708236